Evidence map›Paper›PMID 39304172›Full record

ReviewBiological psychiatry2025

Noradrenergic Mechanisms and Circuitry of Hyperkatifeia in Alcohol Use Disorder.

Florence P Varodayan, Chloe M Erikson, Marcis V Scroger, Marisa Roberto

Abstract readReview
In one paragraph

Review in Biological psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Florence P VarodayanDevelopmental Exposure Alcohol Research Center and Behavioral Neuroscience Program, Department of Psychology, Binghamton University, SUNY, Binghamton, New York. Electronic address: fvaroday@binghamton.edu.
Chloe M EriksonDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, California.
Marcis V ScrogerDevelopmental Exposure Alcohol Research Center and Behavioral Neuroscience Program, Department of Psychology, Binghamton University, SUNY, Binghamton, New York.
Marisa RobertoDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, California. Electronic address: mroberto@scripps.edu.

Funding

Viral Vector CoreP60AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI AMANDA J ROBERTS · 2003 to 2026
$46.3M
Social Anxiety, Stress and Ethanol Sensitivity in Adolescence and AdulthoodP50AA017823 · NIAAA · UPSTATE MEDICAL UNIVERSITY · PI J. DAVID JENTSCH · 2009 to 2026
$30.5M
Neurpsychopharmacology-Multidisciplinary TrainingT32AA007456 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 1985 to 2026
$13.4M
Electrophysiology of alcohol in extended amygdelaU01AA013498 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 2001 to 2026
$12.6M
Neuroplasticity of the Extended Amygdala CRF circuitry in alcohol dependenceR01AA021491 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTO, MARISA · 2013 to 2024
$3.9M
Gene-environment interaction: the brain CRF system in alcohol preferring msP ratsR37AA017447 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTO, MARISA · 2016 to 2025
$3.7M
Neuroimmune mechanisms in stress and alcohol comorbidityR01AA027700 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTO, MARISA · 2019 to 2023
$2.4M
Synaptic Mechanisms underlying sex-differences in alcohol use disorderR01AA029841 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 2022 to 2026
$2.0M
Gene-environment interaction: the brain CRF system in alcohol preferring msP ratsR01AA017447 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTO, MARISA · 2009 to 2013
$1.8M
Alcohol-induced neuroadapation of prefrontal cortical projectionsR00AA025408 · NIAAA · STATE UNIVERSITY OF NY,BINGHAMTON · PI VARODAYAN, FLORENCE PRABHA · 2020 to 2022
$747k
Neuroimmune mechanisms of adult chronic ethanol consumptionR21AA031101 · NIAAA · STATE UNIVERSITY OF NY,BINGHAMTON · PI VARODAYAN, FLORENCE PRABHA · 2023 to 2023
$405k
Alcohol-induced neuroadapation of prefrontal cortical projectionsK99AA025408 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI VARODAYAN, FLORENCE PRABHA · 2017 to 2018
$284k
NIAAA NIH HHS K99 AA025408NIAAA NIH HHS P50 AA017823NIAAA NIH HHS P60 AA006420NIAAA NIH HHS R00 AA025408NIAAA NIH HHS R01 AA017447NIAAA NIH HHS R01 AA021491NIAAA NIH HHS R01 AA027700NIAAA NIH HHS R01 AA029841NIAAA NIH HHS R21 AA031101NIAAA NIH HHS R37 AA017447NIAAA NIH HHS T32 AA007456NIAAA NIH HHS U01 AA013498
6 · The paper itself

Abstract

Hyperkatifeia, the manifestation of emotional distress or pain, is a conceptual framework gaining traction throughout the alcohol and other substance use fields as an important driver of addiction. It is well known that previous or current negative life experiences can serve as powerful motivators for excessive alcohol consumption and precipitate the development of an alcohol use disorder (AUD). A major hallmark of later stages of AUD is the emergence of hyperkatifeia during withdrawal, which can persist well into protracted abstinence to drive relapse. Given these complex interactions, understanding the specific neuroadaptations that lie at the intersection of hyperkatifeia and AUD can inform ongoing therapeutic development. The monoamine norepinephrine is of particular interest. Noradrenergic dysfunction is implicated in AUD, anxiety, chronic stress, depression, and emotional and physical pain. Importantly, there are key sexual dimorphisms within the noradrenergic system that are thought to differentially impact the development and trajectory of AUD in women and men. In the current review, we discuss past and recent work on noradrenergic influences at each stage of the AUD cycle (binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation) through the lens of hyperkatifeia. Evidence from these studies support the prioritization of norepinephrine-specific drug development to treat AUD and the identification of AUD subpopulations that may benefit the most from these therapies (e.g., women or people with comorbid chronic pain or anxiety/stress disorders).

Indexed as

AlcoholismNorepinephrineAnimalsHumansNorepinephrineAdrenergic receptorEthanolNorepinephrine/noradrenalinePrazosinPropranololStress

Identifiers

PMID39304172
PMCPMC11839382

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.